Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant for Abdominally Obese Patients with Impaired Fasting Glucose
NCT00405808Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Dec 2006
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of rimonabant in obesity, impaired fasting glucose (IFG), sponsored by Sanofi. Started Dec 2006; status: terminated.
02
Drugs
rimonabant
03
Conditions
obesityimpaired fasting glucose (IFG)
Beyond the preview
Go deeper on NCT00405808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00405808.